Pharmaceutical Technology's Annual Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Annual Employment Survey
Nearly 1300 pharmaceutical employees provide insights into the issues most relevant to their jobs and the state of the industry workforce today.


Pharmaceutical Technology



Table II: Top five job functions.
Job description. The most common field of expertise was in quality assurance and quality control (20%), followed by pharmaceutical analytical development (11%), pharmaceutical development (10%), validation (8%), and production research and development (7%) (see Table II). On average, participants reported they are contracted to work 38 hours per week and actually work 39 hours per week. For the first time, this average is less than 40 hours per week, which may be attributed to the increased number of part-time work, flexible hours, or company-enforced work schedules. About 88% reported that they do not receive financial reimbursement for extra hours worked. Most employees have worked for their current employer for 8 years.

In 2006 and 2007 the industry underwent several major restructures, closures, and downsizings. A majority of respondents (57%) say they have been through a company downsizing, restructuring, or merger or acquisition in the past two years. Although 37% of respondents indicated these activities changed their job responsibilities, more than 48% reported no significant change in their jobs as a result.

Salary and benefits

Overall results. The mean base annual salary was $90,059 for all respondents, which represents a small increase from last year's average of $88,729. Overall, employees reported an average of $12,162 in additional income from their principal employer, including bonuses, summer work, and grants, and an average of $1531 in additional income from other professional work. Taking into account the average salaries since 1998, it appears the reported annual base salaries have remained at the low $90,000 level since 2004.


Figure 3. Annual salaries of men and women worldwide (overall) and in the United States (US).
Salary by gender only. The biggest change in salary was the increase in women's full-time earnings (see Figure 3). Although the gap between men and women's salaries still exists, it is much smaller than it was last year (a 10% gap versus 20%, respectively). On average, women reported an annual base salary of $83,981, which is nearly $10,000 more than the average reported last year, while their male colleagues earned $92,888 in compensation.


Figure 4. Salary according to job function.
Salary by job function. Jobs in consultancy, pharmaceutical development, and computer information systems were the top-earning fields this year, each reporting an average of more than $100,000 (see Figure 4). Jobs in engineering and finished dosage form manufacturing also are among the highest paid. Employees working in education and preformulation reported the lowest average salaries.


Figure 5. Salary according to region. Southwest (CA, HI, AZ, NM, NV, CO, UT, OK, TX); Southeast (LA, MS, AL, GA, FL, TN, KY, NC, SC, AR, DE, VA, WV, MD, DC); Midwest (OH, IN, IL, IA, MO, MI, MN, WI, KS, ND, SD, NB); Northeast (MA, CT, NY, NJ, PA, VT, NH, RI, ME); and Northwest (OR, WA, ID, MT, WY, AK).
Salary according to location. On average, employees in Northeastern and Southwestern states earned the highest salaries (see Figure 5). These regions also had the greatest number of respondents. Respondents from Puerto Rico reported the lowest average salary of $78,720.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here